<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">1432651</PMID>
      <DateCompleted>
        <Year>1992</Year>
        <Month>12</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2017</Year>
        <Month>11</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">8750-7315</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>82</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>1992</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the American Podiatric Medical Association</Title>
          <ISOAbbreviation>J Am Podiatr Med Assoc</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Warfarin sodium. Practitioner beware.</ArticleTitle>
        <Pagination>
          <StartPage>345</StartPage>
          <EndPage>351</EndPage>
          <MedlinePgn>345-51</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The use of warfarin sodium in the US has increased dramatically over the last 40 years. Warfarin sodium or Coumadin is the most popular oral anticoagulant used in the US. The podiatric physician frequently encounters patients taking this agent and therefore needs to understand its potential impact. This article will familiarize the reader with the history, pharmacology, clinical applications, side effects, and frequent drug interactions encountered with warfarin sodium.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bernard</LastName>
            <ForeName>J M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>J.A. Haley Veterans Hospital, Tampa, FL.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Black</LastName>
            <ForeName>J R</ForeName>
            <Initials>JR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kokseng</LastName>
            <ForeName>C U</ForeName>
            <Initials>CU</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Covey</LastName>
            <ForeName>D F</ForeName>
            <Initials>DF</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Am Podiatr Med Assoc</MedlineTA>
        <NlmUniqueID>8501423</NlmUniqueID>
        <ISSNLinking>1930-8264</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>5Q7ZVV76EI</RegistryNumber>
          <NameOfSubstance UI="D014859">Warfarin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000075202" MajorTopicYN="N">Contraindications</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005528" MajorTopicYN="N">Foot</DescriptorName>
          <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013924" MajorTopicYN="N">Thrombophlebitis</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014859" MajorTopicYN="Y">Warfarin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>35</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1992</Year>
          <Month>7</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1992</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1992</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">1432651</ArticleId>
        <ArticleId IdType="doi">10.7547/87507315-82-7-345</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
